Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07645300
PHASE2

LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

Sponsor: VA Office of Research and Development

View on ClinicalTrials.gov

Summary

The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.

Official title: LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD (LODESTAR) Trial

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2026-10-01

Completion Date

2032-06-30

Last Updated

2026-06-12

Healthy Volunteers

No

Interventions

DRUG

phase 2A Chlorthalidone

very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks

DRUG

phase 2A Spironolactone

very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks

DRUG

phase 2A Chlorthalidone + Spironolactone

very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks

DRUG

phase 2B Chlorthalidone LD + Spironolactone LD

compare combination LD with SPL LD at 12 weeks

Locations (1)

Richard L. Roudebush VA Medical Center, Indianapolis, IN

Indianapolis, Indiana, United States